Published in MMWR Morb Mortal Wkly Rep on March 24, 2006
Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41
Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med (2008) 6.17
Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 4.55
XDR-TB in South Africa: no time for denial or complacency. PLoS Med (2007) 4.20
Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet (2007) 3.65
Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2007) 3.44
Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2009) 2.77
Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis (2010) 2.65
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol (2012) 2.40
Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med (2008) 2.33
Extensively drug resistant tuberculosis. BMJ (2006) 2.29
Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis (2008) 2.26
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis. PLoS Pathog (2009) 2.16
Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis (2010) 2.14
Why is long-term therapy required to cure tuberculosis? PLoS Med (2007) 2.03
Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol (2009) 1.98
Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis (2013) 1.98
Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol (2009) 1.94
Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One (2009) 1.93
Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol (2006) 1.75
Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med (2007) 1.59
Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother (2009) 1.47
Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med (2007) 1.46
Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol (2007) 1.45
Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis (2008) 1.43
Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS One (2007) 1.41
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41
Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa. Ann Thorac Surg (2012) 1.40
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J Clin Microbiol (2012) 1.39
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother (2010) 1.36
Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis (2010) 1.36
Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One (2008) 1.34
Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis (2008) 1.33
Drug-resistant tuberculosis in Shanghai, China, 2000-2006: prevalence, trends and risk factors. Int J Tuberc Lung Dis (2009) 1.31
Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci (2010) 1.26
Mycobacterial phenolic glycolipid virulence factor biosynthesis: mechanism and small-molecule inhibition of polyketide chain initiation. Chem Biol (2007) 1.25
Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci (2007) 1.25
Extensively drug-resistant tuberculosis: a new face to an old pathogen. Annu Rev Med (2009) 1.24
CD4(+) regulatory T cells in a cynomolgus macaque model of Mycobacterium tuberculosis infection. J Infect Dis (2010) 1.24
Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis (2012) 1.24
Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis (2014) 1.23
Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. J Med Chem (2008) 1.22
Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One (2010) 1.20
Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem (2009) 1.19
Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ (2007) 1.19
High diversity of Mycobacterium tuberculosis genotypes in South Africa and preponderance of mixed infections among ST53 isolates. J Clin Microbiol (2009) 1.18
Association between embB codon 306 mutations and drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2007) 1.17
Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen. J Health Popul Nutr (2010) 1.13
Fluorometric assay for testing rifampin susceptibility of Mycobacterium tuberculosis complex. J Clin Microbiol (2008) 1.13
Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother (2014) 1.13
Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. Bull World Health Organ (2007) 1.12
Reaching the targets for tuberculosis control: the impact of HIV. Bull World Health Organ (2007) 1.12
Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrob Agents Chemother (2012) 1.12
Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother (2011) 1.11
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother (2013) 1.10
Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother (2007) 1.09
In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother (2007) 1.09
Extensively drug-resistant tuberculosis, Taiwan. Emerg Infect Dis (2008) 1.08
Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis. Future Microbiol (2013) 1.06
Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. Int J Clin Exp Med (2010) 1.06
Radiological findings of extensively drug-resistant pulmonary tuberculosis in non-AIDS adults: comparisons with findings of multidrug-resistant and drug-sensitive tuberculosis. Korean J Radiol (2009) 1.03
Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California. J Clin Microbiol (2010) 1.03
The chemical biology of new drugs in the development for tuberculosis. Curr Opin Chem Biol (2010) 1.03
DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 1.02
Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol (2014) 1.02
Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping. J Clin Microbiol (2008) 1.01
Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur J Clin Microbiol Infect Dis (2007) 1.01
High-resolution melting curve analysis for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates. J Clin Microbiol (2010) 1.00
Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations. Antimicrob Agents Chemother (2007) 0.99
Declining drug resistance of Mycobacterium tuberculosis isolates from elderly patients in Taiwan, 2000-2008. Eur J Clin Microbiol Infect Dis (2010) 0.99
Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis. Antimicrob Agents Chemother (2007) 0.98
Evaluation of NAD(+) -dependent DNA ligase of mycobacteria as a potential target for antibiotics. Antimicrob Agents Chemother (2007) 0.98
Tuberculosis chemotherapy in the 21 century: Back to the basics. Lung India (2011) 0.97
New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb) (2009) 0.97
Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol Appl (2012) 0.97
Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother (2014) 0.96
Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden. PLoS One (2011) 0.96
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2007) 0.96
Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med (2008) 0.96
Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery. Pharmaceuticals (Basel) (2010) 0.95
Comparison of line probe assay with liquid culture for rapid detection of multi-drug resistance in Mycobacterium tuberculosis. Indian J Med Res (2012) 0.95
Smear Posetive Pulmonary Tuberculosis (PTB) Prevalence Amongst Patients at Agaro Teaching Health Center, South West Ethiopia. Ethiop J Health Sci (2012) 0.95
Synthesis and Antimycobacterial Activity of Symmetric Thiocarbohydrazone Derivatives against Mycobacterium bovis BCG. Iran J Pharm Res (2013) 0.94
Protection elicited by two glutamine auxotrophs of Mycobacterium tuberculosis and in vivo growth phenotypes of the four unique glutamine synthetase mutants in a murine model. Infect Immun (2006) 0.94
Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect Dis (2008) 0.94
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance. Clin Infect Dis (2015) 0.94
Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLoS One (2013) 0.93
Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J Biol Chem (2013) 0.93
Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in zahedan, southeastern iran. Iran Red Crescent Med J (2012) 0.91
Crystal structures of Mycobacterium tuberculosis S-adenosyl-L-homocysteine hydrolase in ternary complex with substrate and inhibitors. Protein Sci (2008) 0.91
Design, synthesis and antimycobacterial activities of 1-methyl-2-alkenyl-4(1H)-quinolones. Bioorg Med Chem (2010) 0.91
The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada. Can J Infect Dis Med Microbiol (2007) 0.90
Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713. J Infect Dis (2013) 0.89
Multicenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary Specimens. J Clin Microbiol (2015) 0.88
From multidrug- to extensively drug-resistant tuberculosis: upward trends as seen from a 15-year nationwide study. PLoS One (2013) 0.88
PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in Mycobacterium tuberculosis. J Antimicrob Chemother (2010) 0.87
Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol (2010) 0.87
Detection of multi-drug resistance & characterization of mutations in Mycobacterium tuberculosis isolates from North- Eastern States of India using GenoType MTBDRplus assay. Indian J Med Res (2014) 0.87
Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep (2006) 37.28
Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep (2009) 17.76
Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep (2010) 14.85
Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004. MMWR Morb Mortal Wkly Rep (2008) 13.54
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2007) 13.20
Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ (2012) 11.57
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ (2014) 11.24
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep (2009) 9.94
Outbreak of West Nile-like viral encephalitis--New York, 1999. MMWR Morb Mortal Wkly Rep (1999) 9.67
Youth risk behavior surveillance - United States, 2009. MMWR Surveill Summ (2010) 9.63
Advancing HIV prevention: new strategies for a changing epidemic--United States, 2003. MMWR Morb Mortal Wkly Rep (2003) 9.37
Youth risk behavior surveillance--United States, 2007. MMWR Surveill Summ (2008) 9.04
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep (2008) 9.02
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morb Mortal Wkly Rep (2011) 8.80
Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep (1999) 8.67
Cigarette smoking among adults--United States, 2004. MMWR Morb Mortal Wkly Rep (2005) 8.60
Vital signs: current cigarette smoking among adults aged ≥18 years--United States, 2005-2010. MMWR Morb Mortal Wkly Rep (2011) 8.45
Annual smoking-attributable mortality, years of potential life lost, and economic costs--United States, 1995-1999. MMWR Morb Mortal Wkly Rep (2002) 8.37
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep (2010) 8.16
Cigarette smoking among adults--United States, 2006. MMWR Morb Mortal Wkly Rep (2007) 8.14
Annual smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 1997-2001. MMWR Morb Mortal Wkly Rep (2005) 8.10
Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep (2009) 8.03
HIV prevalence estimates--United States, 2006. MMWR Morb Mortal Wkly Rep (2008) 7.76
Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep (2002) 7.34
Cigarette smoking among adults--United States, 2000. MMWR Morb Mortal Wkly Rep (2002) 7.32
Notes from the field: electronic cigarette use among middle and high school students - United States, 2011-2012. MMWR Morb Mortal Wkly Rep (2013) 7.28
HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men--five U.S. cities, June 2004-April 2005. MMWR Morb Mortal Wkly Rep (2005) 7.25
Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep (1995) 7.11
Quitting smoking among adults--United States, 2001-2010. MMWR Morb Mortal Wkly Rep (2011) 7.06
Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep (2010) 7.04
Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ (2009) 7.02
Vital signs: HIV prevention through care and treatment--United States. MMWR Morb Mortal Wkly Rep (2011) 6.90
Cigarette smoking among adults--United States, 2007. MMWR Morb Mortal Wkly Rep (2008) 6.82
Vital signs: current cigarette smoking among adults aged >or=18 years --- United States, 2009. MMWR Morb Mortal Wkly Rep (2010) 6.72
Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep (1999) 6.57
Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep (2001) 6.49
Prevalence and awareness of HIV infection among men who have sex with men --- 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep (2010) 6.25
Youth risk behavior surveillance--United States, 2013. MMWR Surveill Summ (2014) 6.17
Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2009) 6.09
Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep (2009) 6.08
Tobacco use among middle and high school students - United States, 2011-2014. MMWR Morb Mortal Wkly Rep (2015) 6.05
National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ (2007) 6.05
Cigarette smoking among adults and trends in smoking cessation - United States, 2008. MMWR Morb Mortal Wkly Rep (2009) 6.04
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep (2008) 6.02
CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep (2012) 5.77
Cluster of severe acute respiratory syndrome cases among protected health-care workers--Toronto, Canada, April 2003. MMWR Morb Mortal Wkly Rep (2003) 5.50
Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2011) 5.48
Trends in the prevalence and incidence of self-reported diabetes mellitus -- United States, 1980-1994. MMWR Morb Mortal Wkly Rep (1997) 5.45
Surveillance for dental caries, dental sealants, tooth retention, edentulism, and enamel fluorosis--United States, 1988-1994 and 1999-2002. MMWR Surveill Summ (2005) 5.40
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep (1997) 5.30
Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep (2009) 5.29
Severe acute respiratory syndrome--Singapore, 2003. MMWR Morb Mortal Wkly Rep (2003) 5.28
Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep (2009) 5.25
Tobacco use among adults--United States, 2005. MMWR Morb Mortal Wkly Rep (2006) 5.24
Human immunodeficiency virus (HIV) risk, prevention, and testing behaviors--United States, National HIV Behavioral Surveillance System: men who have sex with men, November 2003-April 2005. MMWR Surveill Summ (2006) 5.15
Prevalence of disabilities and associated health conditions among adults--United States, 1999. MMWR Morb Mortal Wkly Rep (2001) 5.14
Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep (2012) 5.12
Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May, 2009. MMWR Morb Mortal Wkly Rep (2009) 5.10
Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep (2001) 4.95
Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep (2009) 4.86
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85
Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. MMWR Morb Mortal Wkly Rep (1993) 4.77
Surveillance for Lyme disease--United States, 1992-2006. MMWR Surveill Summ (2008) 4.77
Barriers to children walking and biking to school--United States, 1999. MMWR Morb Mortal Wkly Rep (2002) 4.76
Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep (2011) 4.68
Subpopulation estimates from the HIV incidence surveillance system--United States, 2006. MMWR Morb Mortal Wkly Rep (2008) 4.68
Ebola viral disease outbreak--West Africa, 2014. MMWR Morb Mortal Wkly Rep (2014) 4.67
Cancer screening - United States, 2010. MMWR Morb Mortal Wkly Rep (2012) 4.64
Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008. MMWR Recomm Rep (2008) 4.64
Estimating the future number of cases in the Ebola epidemic--Liberia and Sierra Leone, 2014-2015. MMWR Surveill Summ (2014) 4.53
Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) Virus - United States, 2009. MMWR Morb Mortal Wkly Rep (2009) 4.50
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2014) 4.50
Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep (2009) 4.48
Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep (2012) 4.45
Current cigarette smoking among adults - United States, 2005-2012. MMWR Morb Mortal Wkly Rep (2014) 4.39
Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep (2005) 4.39
Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep (2005) 4.36
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep (2009) 4.36
Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep (2009) 4.36
FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep (2010) 4.34
HIV surveillance--United States, 1981-2008. MMWR Morb Mortal Wkly Rep (2011) 4.30
Forward: CDC Health Disparities and Inequalities Report - United States, 2011. MMWR Surveill Summ (2011) 4.29
Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep (2010) 4.24
Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. MMWR Recomm Rep (2013) 4.22
National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010. MMWR Morb Mortal Wkly Rep (2011) 4.18
Trends in aging--United States and worldwide. MMWR Morb Mortal Wkly Rep (2003) 4.16
Racial/ethnic disparities in diagnoses of HIV/AIDS--33 states, 2001-2005. MMWR Morb Mortal Wkly Rep (2007) 4.16
Methicillin-resistant staphylococcus aureus infections among competitive sports participants--Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep (2003) 4.14
Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb Mortal Wkly Rep (2012) 4.13
Ebola virus disease outbreak - Nigeria, July-September 2014. MMWR Morb Mortal Wkly Rep (2014) 4.08
Global youth tobacco surveillance, 2000-2007. MMWR Surveill Summ (2008) 3.98
Vital signs: central line-associated blood stream infections--United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep (2011) 3.98
Impact of an innovative approach to prevent mother-to-child transmission of HIV--Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep (2013) 3.96
Update: Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep (2003) 3.95
Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep (2002) 3.95
Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001--2009. MMWR Morb Mortal Wkly Rep (2011) 3.92
Locally acquired Dengue--Key West, Florida, 2009-2010. MMWR Morb Mortal Wkly Rep (2010) 3.83